Prior authorisation: difference between revisions
Diff·revision 12 → 13·22:36, 9 May 2025
Difference between revision 12 and revision 13 of Prior authorisation. 3 lines changed; the page grew by 291 bytes.
| Revision 12 — 00:08, 26 Apr 2025 AnalyticalAnnie (talk) expand §How it operates 3,226 bytes +132 | Revision 13 — 22:36, 9 May 2025 TelehealthTruus (talk) move a stray full stop inside the reference 3,517 bytes +291 | ||
|---|---|---|---|
| 31 | The last row is where this intersects with the rest of the wiki. Where a licensed product is unaffordable or coverage is denied, some people obtain material outside licensed channels, with the identity, content and sterility uncertainties this wiki documents throughout.{{r|reports}} | 31 | The last row is where this intersects with the rest of the wiki. Where a licensed product is unaffordable or coverage is denied, some people obtain material outside licensed channels, with the identity, content and sterility uncertainties this wiki documents throughout.{{r|reports}} |
| 32 | 32 | ||
| + | 33 | That is a description of an observed pattern, not an endorsement of it. Research-use compounds are not approved for human administration.{{r|usp1503}} | |
| + | 34 | ||
| 33 | == References == | 35 | == References == |
| 34 | {{reflist}} | 36 | {{reflist}} |
| ⋮ | ⋮ | ||
| 36 | <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> | 38 | <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> |
| 37 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | 39 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 38 | 41 | ||
| 39 | == See also == | 42 | == See also == |